FGP
JANX icon

Freestone Grove Partners’s Janux Therapeutics JANX Stock Holding History

Freestone Grove Partners’s Portfolio JANX Stock Details JANX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-41,806
Closed -$577K – 1087
2025
Q4 		$577K Buy
+41,806
New +$983K ﹤0.01% 548
2025
Q1 		– Sell
-6,807
Closed -$364K – 690
2024
Q4 		$364K Buy
+6,807
New +$360K ﹤0.01% 432

Other funds holding JANX

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Freestone Grove Partners's JANX Position: Q1 2026 in Review

Freestone Grove Partners sold out of Janux Therapeutics (JANX) in Q1 2026, closing a stake of 41,806 shares — an estimated $577K sold.

Freestone Grove Partners first reported a position in JANX in Q4 2024 and held it in 2 quarters. The position peaked at $577K in Q4 2025. 190 funds tracked by Wall St. Rank hold JANX as of Q1 2026.

  • Freestone Grove Partners reported no remaining Janux Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Freestone Grove Partners sold 41,806 Janux Therapeutics shares in Q1 2026, an estimated $577K.
  • Freestone Grove Partners first reported a position in Janux Therapeutics in Q4 2024 and held it in 2 quarters.
  • Freestone Grove Partners's Janux Therapeutics position peaked at $577K in Q4 2025.
  • 190 funds tracked by Wall St. Rank held Janux Therapeutics as of Q1 2026.

Based on Freestone Grove Partners's 13F filing for Q1 2026, filed 15 May 2026.